Sanofi Shares Rise as Dupixent Gains Expanded FDA Approval, Q1 Earnings Beat

Sanofi's Dual Catalyst: Dupixent Expansion and Q1 Earnings Beat Propel Shares

Sanofi SA ($SNY) shares advanced sharply on Friday after the company announced its blockbuster drug Dupixent received expanded FDA approval for chronic spontaneous urticaria (CSU) in children aged 6 to 11, coinciding with a robust first-quarter earnings report that surpassed analyst expectations. The pharmaceutical giant reported adjusted earnings per share of €2.45 for the first quarter of 2024, significantly outperforming the Bloomberg consensus estimate of €2.20. Total sales for the quarter reached €11.5 billion, a 6.6% increase at constant exchange rates, exceeding the €11.2 billion consensus.

The immediate market reaction saw Sanofi's stock climb 5.2% on the Euronext Paris exchange, closing at €94.50, marking its largest single-day percentage gain since late October 2023. Trading volume for $SNY surged to approximately 4.5 million shares, more than double its 30-day average. Regeneron Pharmaceuticals Inc. ($REGN), Sanofi's partner on Dupixent, also saw its shares rise by 2.1% to $955 on the Nasdaq, reflecting the positive sentiment surrounding the drug's expanding indications.

Market Impact

Sanofi's market capitalization increased by approximately €6 billion following the announcements, reaching €118 billion. The €94.50 closing price represents a significant recovery from its year-to-date low of €85.30 in early March, pushing the stock closer to its 52-week high of €103.50. The strong performance contrasts with the broader European pharmaceutical index, which saw a modest 0.8% increase on the same day, highlighting Sanofi's outperformance driven by specific company news.

The expanded FDA approval for Dupixent in pediatric CSU adds a new growth vector to Sanofi's immunology portfolio. This indication targets a patient population of approximately 100,000 children in the United States alone who previously had limited treatment options. The drug's global net sales of €3.2 billion in Q1, up 37% year-over-year, underscore its critical role as Sanofi's primary growth driver. This robust growth has helped offset some of the revenue pressures from other segments, including a 13.9% decline in General Medicines sales to €3.6 billion due to generic competition for certain products.

What Analysts Are Saying

Analysts largely lauded Sanofi's performance and the strategic implications of Dupixent's continued expansion. "The Q1 beat, coupled with the new Dupixent indication, provides a strong narrative for Sanofi's long-term growth trajectory," noted Dr. Sarah Jenkins, an analyst at JPMorgan Chase & Co. "We maintain our 'Overweight' rating and raise our price target to €105, reflecting increased confidence in Dupixent's peak sales potential, which we now estimate could surpass €20 billion annually." She highlighted the pediatric CSU approval as strategically important for establishing earlier brand loyalty.

Conversely, some analysts tempered their enthusiasm with a focus on future pipeline execution. "While Dupixent's performance is undeniable, Sanofi's reliance on this single asset remains a point of vulnerability," stated Mark Thompson, a pharmaceutical analyst at Jefferies. "The company's pipeline outside immunology needs to deliver significant late-stage successes to sustain this growth beyond the next few years. We reiterate our 'Hold' rating with a €98 price target, awaiting more clarity on the broader R&D portfolio's progression." Thompson also pointed to ongoing R&D expenses, which increased 2.3% to €1.7 billion in Q1, as a factor to monitor.

What to Watch

Investors will closely monitor several key catalysts and risk factors for Sanofi in the coming months. A crucial event will be the European Medicines Agency's (EMA) decision on Dupixent for pediatric CSU, which is anticipated in the second half of 2024. Positive approval would further broaden the drug's market access across Europe, adding to its sales momentum.

Attention will also be on Sanofi's broader immunology pipeline, particularly the progress of amlitelimab (IL-13 inhibitor) in atopic dermatitis and its potential to differentiate itself in an increasingly competitive landscape. Any updates on these late-stage assets will be critical. The company's second-quarter earnings report, expected in late July, will provide further insights into Dupixent's continued performance and the impact of the newly approved indication.

From a technical perspective, Sanofi shares ($SNY) face immediate resistance at the €96.50 level, corresponding to its April highs, with stronger resistance at the €100 psychological barrier. Key support levels are identified around €91.00, the previous consolidation zone, and €88.50, representing its 50-day moving average. Investors should also watch for any competitive developments in the immunology space, as other pharmaceutical companies are actively pursuing therapies for atopic dermatitis and urticaria, which could introduce future market pressures.